Remdesivir Can Help Vulnerable Patient Populations: An Interview With Anu Osinusi

Anu Osinusi, Vice President, Clinical Research for Hepatitis, Respiratory, and Emerging Viruses at Gilead Sciences joined DocWire News to discuss data on the use of Veklury® (remdesivir) in vulnerable populations. Data highlights include:

• Results from a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study (REDPINE) that examined the use of remdesivir in people with moderately and severely reduced kidney function hospitalized for COVID-19, a population at higher risk of progression to severe COVID-19.
• A real-world evidence study that examined Veklury’s effectiveness in reducing COVID-19 mortality for people living with cancer hospitalized for COVID-19.
• A real-world evidence study looking at the association between Veklury and risk of hospital readmission for people who are immunocompromised and hospitalized for COVID-19. Results looked at both 30- and 60-day readmission rates compared to matched controls.

This study included people living with immunocompromised conditions such as cerebrovascular disease, congestive heart failure, dementia, diabetes (with chronic complications), peripheral vascular disease, hypertension with complications and secondary hypertension, chronic kidney disease, and chronic neurologic conditions.